Viberzi is a medicine for adults with irritable bowel syndrome that causes diarrhea (IBS-D). It is taken as a pill. It works on nerve receptors in the gut to slow things down and ease belly pain and diarrhea.
Every report comes from a Lived member, sent anonymously.
Have you tried Viberzi (Eluxadoline) for IBS (Irritable Bowel Syndrome)?
Eluxadoline, sold in the US as Viberzi, is a prescription tablet for adults with irritable bowel syndrome with diarrhea (IBS-D). Irritable bowel syndrome is a common, long-term problem of the large intestine that causes cramping, bloating and changes in bowel habits without damaging the bowel itself. In the diarrhea-predominant type, frequent loose or watery stools and belly pain are the main burden. Eluxadoline is one of several prescription medicines for IBS-D. The American Gastroenterological Association gives it a conditional recommendation based on moderate-certainty evidence, meaning it is a reasonable choice for many people with IBS-D but not automatically the right one. Whether it fits depends heavily on medical history: people who have had their gallbladder removed, and several other groups described below, should not take it. It is not approved for children or for IBS with constipation.
The bowel wall has its own opioid receptors, part of the same receptor family that pain medicines like morphine act on. When these receptors are switched on, the muscular waves that push stool along slow down. Eluxadoline activates two types of these receptors (mu and kappa) and blocks a third (delta), and it works mainly in the gut. Slower bowel activity gives stools more time to firm up, which is how it reduces diarrhea and urgency. The same opioid action can also cause a spasm that blocks the flow of bile and pancreatic juices into the small intestine. That spasm is the source of the medicine's most serious risk, inflammation of the pancreas (pancreatitis), and it is why the gallbladder and alcohol history matter so much before starting. Because very high doses can produce a sense of euphoria, eluxadoline is a Schedule IV controlled substance in the US, although euphoria was rare at prescribed doses in clinical trials.
Eluxadoline is a tablet taken twice a day with food. The usual adult dose is 100 mg twice daily. A lower 75 mg dose is used for people who do not tolerate the higher dose, people with mild or moderate liver problems or reduced kidney function, and people taking certain medicines that raise eluxadoline levels in the blood. If a dose is missed, take the next one at the usual time rather than doubling up. Because it is a controlled substance, prescriptions and refills follow stricter rules than for most medicines, and the tablets should not be shared.
Constipation, nausea and abdominal pain are the most common side effects. Constipation usually shows up early: about half of cases in the trials began within the first two weeks. Vomiting, bloating, gas, dizziness and rash are less common. About 8 percent of trial participants stopped because of side effects, compared with 4 percent on placebo. A few reactions need action rather than patience. Stop eluxadoline and get medical care right away for new or worsening upper belly pain, especially pain that spreads to the back or shoulder, with or without nausea and vomiting; this can signal pancreatitis or a bile duct spasm, and most serious cases began within the first week, some after only one or two doses. Stop it and call the prescriber right away for severe constipation, which in rare cases has led to bowel blockage or a tear in the bowel. Serious allergic reactions have also occurred, sometimes after the first doses: swelling of the face or throat, throat tightness or trouble breathing is an emergency that needs a 911 call.
The most important warning concerns the gallbladder. People without a gallbladder should not take eluxadoline, because serious pancreatitis, including deaths, has occurred mainly in that group. It is also not for people who have had pancreatitis or other pancreas disease, a blocked bile duct or bile duct spasm problems, severe liver impairment, chronic or severe constipation, or a known bowel blockage. People who regularly drink more than three alcoholic drinks a day, or who have an alcohol use problem, should not take it either, and heavy drinking should be avoided during treatment because it raises the risk of pancreatitis. Avoid combining eluxadoline with other medicines that slow the bowel, such as opioid pain medicines, alosetron (another prescription IBS-D medicine) and anticholinergic drugs (used for bladder spasms, allergies and other conditions). Loperamide (Imodium), an over-the-counter diarrhea remedy, can be used now and then for a bad bout of diarrhea, but not regularly, and should be stopped if constipation starts. Eluxadoline raises blood levels of rosuvastatin (Crestor), a cholesterol medicine, so the lowest effective statin dose is used. In the other direction, some medicines raise eluxadoline levels and call for the 75 mg dose, including cyclosporine (an immune-suppressing drug), gemfibrozil (a triglyceride medicine), rifampin (an antibiotic), eltrombopag (a platelet-boosting drug) and several HIV medicines such as ritonavir. There are no studies in pregnancy or breastfeeding, so anyone pregnant, planning pregnancy or nursing should weigh the choice with the prescriber.
In the main trials, eluxadoline helped a minority of people meet a demanding goal: less pain and firmer stools on the same days, on at least half of days over 12 weeks. About a quarter to a third of people on 100 mg reached that goal, compared with roughly one in six on placebo. The clearest effect was on stool consistency; pain improvement on its own was not clearly better than placebo. The advantage over placebo was maintained through six months of treatment, and symptoms did not rebound above their starting level when the medicine was stopped in a short withdrawal period. The first weeks matter most for safety, since constipation and the rare pancreas and bile duct reactions usually appear early. After that, follow-up focuses on whether diarrhea and urgency have improved enough to justify continuing. If they have not, there are other prescription options for IBS-D, and diet changes, stress management and other approaches to IBS remain part of care.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Viberzi (Eluxadoline), what you've noticed, or ask the community a question.